Proprietary AI analyst is now available

Abeona Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Abeona Therapeutics and similar public comparables like Racura Oncology, Cybin, Luzhu Biotech, Medy-Tox and more.

Abeona Therapeutics Overview

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.


Founded

1974

HQ

United States

Employees

136

Financials (LTM)

Revenue: $35M
Net Income: $17M

EV

$183M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Abeona Therapeutics Financials

Abeona Therapeutics reported last 12-month revenue of $35M.

In the same LTM period, Abeona Therapeutics generated $26M in gross profit and $17M in net income.

Revenue (LTM)


Abeona Therapeutics P&L

In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of $79M.

Abeona Therapeutics is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.

See analyst estimates for Abeona Therapeutics
LTMLast FY202320242025202620272028
Revenue$35M$6M$4M-$6M
Gross Profit$26M$2M$2M-$2M
Gross Margin76%41%54%-41%
EBITDA-$79M($51M)($57M)$79M
EBITDA Margin-1350%(1445%)-1350%
EBIT Margin(206%)(1537%)(1377%)-(1537%)
Net Profit$17M$71M($54M)($64M)$71M
Net Margin49%1223%(1548%)-1223%

Financial data powered by Morningstar, Inc.

Abeona Therapeutics Stock Performance

Abeona Therapeutics has current market cap of $328M, and enterprise value of $183M.

Market Cap Evolution


Abeona Therapeutics' stock price is $5.75.

Abeona Therapeutics share price decreased by 0.9% in the last 30 days, and increased by 1.2% in the last year.

Abeona Therapeutics has an EPS (earnings per share) of $1.25.

See more trading valuation data for Abeona Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$183M$328M-0.3%-0.9%28.3%1.2%$1.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Abeona Therapeutics Valuation Multiples

Abeona Therapeutics trades at 5.3x EV/Revenue multiple, and 2.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Abeona Therapeutics

EV / Revenue (LTM)


Abeona Therapeutics Financial Valuation Multiples

As of June 23, 2026, Abeona Therapeutics has market cap of $328M and EV of $183M.

Abeona Therapeutics has a P/E ratio of 19.2x.

LTMLast FY202320242025202620272028
EV/Revenue5.3x31.4x52.2x-31.4x
EV/EBITDA-2.3x(3.6x)(3.2x)2.3x
EV/EBIT(2.6x)(2.0x)(3.8x)(2.8x)(2.0x)
EV/Gross Profit6.9x76.3x96.4x-76.3x
P/E19.2x4.6x(6.0x)(5.1x)4.6x
EV/FCF-(2.2x)(4.9x)(3.1x)(2.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Abeona Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Abeona Therapeutics Margins & Growth Rates

Abeona Therapeutics grew revenue by 1039% but net profit decreased by 159% in the last fiscal year.

In the most recent fiscal year, Abeona Therapeutics reported gross margin of 41%, EBITDA margin of 1350%, and net margin of 1223%.

See estimated margins and future growth rates for Abeona Therapeutics

Abeona Therapeutics Margins

Last FY20252026202720282029
Gross Margin41%41%76%
EBITDA Margin1350%1350%-
EBIT Margin(1537%)(1537%)(77%)
Net Margin1223%1223%(64%)
FCF Margin(1448%)(1448%)-

Abeona Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth1039%(100%)-1039%
Gross Profit Growth2012%(100%)-2012%
EBITDA Growth-12%(239%)-
EBIT Growth(43%)33%39%(43%)
Net Profit Growth(159%)18%(212%)(159%)
FCF Growth-57%44%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Abeona Therapeutics Operational KPIs

Abeona Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Access forward-looking KPIs for Abeona Therapeutics
LTMLast FY20232025202620272028
Revenue per Employee-$0.0M--
Opex per Employee-$0.7M--
G&A Expenses to Revenue213%1117%543%1117%
R&D Expenses to Revenue69%461%888%461%
Opex to Revenue-1578%1431%1578%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Abeona Therapeutics Competitors

Abeona Therapeutics competitors include Racura Oncology, Cybin, Luzhu Biotech, Medy-Tox, Dong-A Socio Holdings, Amarin Corp, OmniAb, Opus Genetics, Palisade Bio and Biofarm.

Most Abeona Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Racura Oncology-92.4x-(91.6x)
Cybin----
Luzhu Biotech-6.7x(14.4x)158.2x
Medy-Tox2.3x2.3x18.8x14.7x
Dong-A Socio Holdings0.7x0.6x5.5x5.8x
Amarin Corp0.1x0.2x(0.9x)(0.8x)
OmniAb16.4x12.5x(6.8x)(7.7x)
Opus Genetics19.5x18.8x(5.8x)-

This data is available for Pro users. Sign up to see all Abeona Therapeutics competitors and their valuation data.

Start Free Trial

Abeona Therapeutics VC Funding History

Before going public, Abeona Therapeutics raised $4M in total equity funding, across 2 rounds.


Abeona Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-14Seed-$4M--
Dec-13Seed-$800K--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Abeona Therapeutics

When was Abeona Therapeutics founded?Abeona Therapeutics was founded in 1974.
Where is Abeona Therapeutics headquartered?Abeona Therapeutics is headquartered in United States.
How many employees does Abeona Therapeutics have?As of today, Abeona Therapeutics has over 136 employees.
Who is the CEO of Abeona Therapeutics?Abeona Therapeutics' CEO is Vishwas Seshadri.
Is Abeona Therapeutics publicly listed?Yes, Abeona Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Abeona Therapeutics?Abeona Therapeutics trades under ABEO ticker.
When did Abeona Therapeutics go public?Abeona Therapeutics went public in 1980.
Who are competitors of Abeona Therapeutics?Abeona Therapeutics main competitors include Racura Oncology, Cybin, Luzhu Biotech, Medy-Tox, Dong-A Socio Holdings, Amarin Corp, OmniAb, Opus Genetics, Palisade Bio, Biofarm.
What is the current market cap of Abeona Therapeutics?Abeona Therapeutics' current market cap is $328M.
What is the current revenue of Abeona Therapeutics?Abeona Therapeutics' last 12 months revenue is $35M.
What is the current revenue growth of Abeona Therapeutics?Abeona Therapeutics revenue growth (NTM/LTM) is 192%.
What is the current EV/Revenue multiple of Abeona Therapeutics?Current revenue multiple of Abeona Therapeutics is 5.3x.
What is the current net income of Abeona Therapeutics?Abeona Therapeutics' last 12 months net income is $17M.
How many companies Abeona Therapeutics has acquired to date?Abeona Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Abeona Therapeutics has invested to date?Abeona Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Abeona Therapeutics

Lists including Abeona Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial